AB Corporate Bond ETF (NASDAQ:EYEG) Shares Pass Below 50-Day Moving Average – Here’s Why

Posted by Andrew Walz on Sep 10th, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $34.68 and traded as low as $34.38. AB Corporate Bond ETF shares last traded at $34.39, with a volume of 23 shares.

AB Corporate Bond ETF Stock Down 0.4%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The firm has a market cap of $27.29 million, a price-to-earnings ratio of -20.30 and a beta of 0.18. The firm has a 50-day moving average price of $34.64 and a two-hundred day moving average price of $35.09.

AB Corporate Bond ETF Cuts Dividend

The business also recently disclosed a monthly dividend, which was paid on Friday, September 4th. Stockholders of record on Tuesday, September 1st were given a dividend of $0.1284 per share. This represents a c) annualized dividend and a dividend yield of 4.5%. The ex-dividend date was Tuesday, September 1st. AB Corporate Bond ETF’s payout ratio is currently -101.79%.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in AB Corporate Bond ETF stock. Kestra Advisory Services LLC purchased a new position in shares of AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned approximately 0.13% of AB Corporate Bond ETF at the end of the most recent reporting period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About AB Corporate Bond ETF

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.